Optimal management for axillary recurrence is poorly understood. The aim of this study was to evaluate the risk factors for overall survival in the patients with axillary recurrence. Data of 1098 patients were collected from breast cancer registers from Clinic for Oncology Nis between 1990-1995. All patients underwent modified radical mastectomy. Axillary recurence was diganosed in 43(3.92%) patients. Most patients were presented with a localized, palpable axillary mass 30(69.77%). Cox multivariate analysis of prognostic factors for breast cancer-specific survival showed that node status HR 4.69 (1.50 to 14.72), tumor size HR 3.18 (0.90 to 11.26) and axillary radiotherapy HR 1.99 (0.69 to 5.75) had statistically significant effect on breast cancer mortality. Log-rank (54.21 p<0.001) analysis showed significant difference for overall survival among women with a axillary recurrence based on different cancer stages. Tumor size and node status were the most important prognostic factors in women with axillary recurrence.
INTRODUCTION

B
reast cancer is one of the most feared and serious diseases affecting women. The management of breast cancer presents many challenges unique to this specific group of patients. The role of axillary node dissection on breast cancer axillary recurrence and survival is not quite clear. However, surgical staging of axilla via level I/II during axillary lymph node dissection (ALND) is well-established and effective means of controlling regional metastases from breast cancer. Reported rates of axillary node recurrences after ALND are generally less than 3% [1] [2] [3] [4] [5] [6] . As ALND has been a standard component of breast cancer management for several decades, there are limited data available regarding the significance of axillary regional nodal failure, related to initial breast cancer stage at diagnosis, and even less is known about the optimal management approach for these patients.
The number of retrieved and number of involved nodes are risk factors for axillary recurrence 1, 4, 5, [7] [8] [9] [10] [11] . Patient age 7, 12, 13 , histological grade 12 , tumor size 7, 14 , presence of extra capsular extension of tumor 8, 11 and location of the primary tumor 15 have also been implicated as possible risk factors. The prognosis in patients with axillary recurrence is poor, but survival estimates in most series was difficult to interpret owing to the small number of patients.
Recurrent breast cancer is often responsive to therapy, although treatment is rarely curative at this stage of disease. However, patients with localized axillary recurrences may be long-term survivors with appropriate therapy. Therefore, prior to recurrent cancer treatment, restaging to evaluate the extent of disease is indicated.
The aim of this study was to evaluate the risk factors for overall survival in the patients with axillary recurrence.
MATERIAL AND METHOD
Data of 1098 patients were collected from breast cancer registers from Clinic for Oncology Nis between 1990-1995. All patients underwent modified radical mastectomy. Of these, 43(3.92%) were diganosed with axillary recurence as an initial site of disease relapse. These group of patients were followed until 2002. The medical data of patients with axillarr recurence were reviewed utilizing a standard coding sistem. Staging was based on surgical pathologic findings unless the patients received induction chemotherapy. Median follow up was 78.4 mounths from the time of initial diagnosis.
To study the joint effect of different variables on prognosis for axillary recurrence patients, multivariate proportional hazards model 16 Most patients -38(88.37%) received multimodality therapy. The most common sequence of multimodality therapy was surgery followed by either systemic therapy or axillary irradiation. Three patients (6.98%) had only irradiation, and 2(4.45%) patients had surgical resection only as a modality of axillary recurrence treatment. (Table 2 )
PROGNOSIS IN WOMEN WITH AXILLARY RECURRENCE
During the follow-up 24 of 43 women with axillary recurrence died, 21 from breast cancer. Two of 43 women were noted to have distant metastases within 3 months.
Cox multivariate analysis of prognostic factors for breast cancer-specific survival showed that node status (RH 4.69 (1.50 to 14.72); p=0.008) had a statistically significant effect on breast cancer mortality. The same applied to tumor size (RH 3.18 (0.90 to 11.26); p=0.073) and axillary radiotherapy (RH 1.99 (0.69 to 5.75); p=0.056). (table 3) The median survival time in stage O and I could not be determined, (no events in these stages).
In stage II the median survival time was 82.11 months (95%CI 75.69 to 88.52) and 24.28 months (95%CI 13.66 to 34.90) in stage III.
Log Rank analysis showed statisticlly significant differences for overall survival among women with axillary recurrence based on different cancer stages (Log Rank 54.21 p<0.001). (figure 1)
DISCUSSION
Management of the axilla in breast cancer patients remains controversial. The approach for patients with a clinically positive axilla is relatively more straightforward. This scenario generally mandates complete ALND to avoid the risks of regional disease progression, which can result in substantial morbidity from brachial plexopathy. Radiation therapy is suboptimal in controlling the tumor burden associated with clinically obvious disease. In the 1-year results of the NSABP B-04 study (3) , nearly 600 patients with clinically positive axilla were randomized to undergo radical mastectomy versus total mastectomy with axillary irradiation. The axilla was the site of first failure in 11.9% of the irradiated patients versus 1% of patients with the axilla surgically treated. Development of standardized approach to managing the clinically negative axilla has been exceedingly difficult, however, because of evolving paradigms regarding the indications for adjuvant systemic therapy and because of insufficient data regarding the survival impact associated with standard level I/II ALND. The contribution of ALND to long term breast cancer outcome has been questioned since the publication of findings from the NSABP B-04 study. This randomized prospective study demonstrated survival equivalence in 10 year period in patients with clinically node negative disease, regardless of whether the patients were treated with radical mastectomy, total mastectomy with axilla irradiation, or total mastectomy with no treatment to the axilla 3 . In the initial Adjuvant tamoxifen 12 (27.91%) clinically node negative patients randomized to undergo total mastectomy alone, had an axillary recurrence requiring delayed dissection 4 . Subsequent review of the study participants has revealed, however, that many patients randomized to undergo total mastectomy did in fact have some axillary lymph nodes resected from the surgical specimen 5, 17 . The risk of axillary recurrence necessitating delayed ALND was inversely related to the number of lymph nodes removed at the time of total mastectomy, and axillary failure rate was actually 21%,when this issue was taken into account. It should also be noted that the sample size of the NSABP B-04 study would not have been adequate to detect the presence of a small survival benefit conferred by ALND, if the node does exist at all.
The utility of ALND has also been challenged on the grounds that findings from ALND do not necessarily influence treatment decisions. The overview analysis demonstrates that adjuvant systemic therapy is associated with an approximate of 30% reduction in the odds of recurrence for both node negative and node positive patients 7 Because of these issues, several oncologists have proposed that ALND should be avoided completely in patients with low risk disease, such as T1 a cancer 11 or in those patients, undergoing less invasive methods of surgical axilla evaluation, such as lymphatic mapping and sentinel lymph node biopsy. Preliminary data indicate that sentinel lymph node biopsy is an accurate means of predicting axillary nodal status in more than 95% of the cases 12, 14, 18 . The American College of Surgeons Oncology Group is currently conducting a prospective, randomized study designed to evaluate this question, and this study will also answer the question of whether ALND does contribute to long-term survival. The data from this study will be mature, though, several years from now.
For those patients in whom ALND is deferred, it is known that axillary irradiation does result in low rates of regional nodal relapse, however, radiation of axillary nodal basin can result in long-term adverse side effects that are comparable with those of ALND 1, 3, 6, [19] [20] [21] . In patients with positive nodes ranging between zero and three after level I and II ALND, axillary irradiation confers no or little benefit, and increases the risk of lymphedema 22 . In a review of axillary failure following mastectomy, Morrow 23 notes that reported rates range from 0.1% to 7.9%, with most series reporting rates less than 2%. The finding of pathologically positive axillary disease at the time of diagnosis is probably the most reliable predictor of regional nodal failure. Recht 24 found axillary recurrences ranging from 15% to 40% in patients undergoing mastectomy who are found to be histological node positive, and he notes that it is exceedingly difficult to identify other patient and tumor features associated with increased risk for axillary failure, because these features usually determine primary disease treatment decisions.
In summary, the present study is in agreement with historical data indicating that the risk of axillary failure from breast cancer is not very high. This pattern of relapse can, however, be manifested in all stages of initial diagnosis, and appears to be controlled with multimodality treatment approach that includes a surgical component. Axillary recurrence is more common in younger women with large tumors. Radiotherapy to the breast was protective. Tumor size and nodal status were the most important prognostic factors in women with axillary recurrence. Long-term survival is achieved in about one half of the patients, and tends to be more likely in patients with earlier stage disease at the time of initial diagnosis.
REZIME
Optimalni tretman aksilarnog recidiva nije jasno odredjen. Cilj ovog rada je da utvrdi faktore rizika za du'inu pre'ivaljavanje bolesnica sa aksilarnim recidivom. Razmatrani su podaci 1098 bolesnica le~enih na Onkolo{koj klinici Ni{ u periodu 1990-1995. Sve bolesnice bile su podvrgnute modifikovanoj radikalnoj mastektomiji. Aksilarni recidiv dijagnostifikovan je kod 43(3.92%) bolesnica. Kod ve}ine bolesnica bio je prisutan lokalizovani, palpabilni aksilarni tumefakt 30(69.77%). Cox-ova multivariantna analiza prognosti~kih faktora za du'inu pre'ivljavanja kod bolesnica sa karcinomom dojke pokazala je da su limfonodalni status HR 4.69 (1.50 to 14.72), veli~ina tumora HR 3.18 (0.90 to 11.26) i aksilarna radioterapija HR 1.99 (0.69 to 5.75) imali statisti~ku zna~ajnost na mortalitet uzrokovan karcinomom dojke. Kaplan-Meier-ova analiza (54.21 p<0.001) pokazuje zna~ajne razlike u du'ini pre'ivljavanja kod razli~itih stadijuma bolesti. Veli~ina tumora i limfonodalni status su najzna-~ajniji prognosti~ki faktori kod bolesnica sa aksilarnim recidivom.
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